Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies. Update December 2022

Rothschedl, E. and Wolf, S. (2022): Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies. Update December 2022. Oncology Fact Sheet Nr. 107.

[thumbnail of Oncology Fact Sheet Nr.107_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
485kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 107
Deposited on:	25 Aug 2022 14:38
Last Modified:	27 Dec 2022 12:48

Repository Staff Only: item control page